NCT07504588
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 25 versions: 15 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 22 → 27 locations
- Minor Study sites: 27 to 28
- Minor Study sites: 23 to 27
- Minor Trial sites expanded: 19 → 22 locations
- Minor Study sites: 21 to 22
- Minor Study sites: 19 to 21
- Minor Trial sites expanded: 12 → 19 locations
- Minor Trial sites expanded: 9 → 12 locations
- Minor Study sites: 10 to 12
- Minor Study sites: 9 to 10
- Minor Study sites: 7 to 9
- Minor Trial sites expanded: 4 → 7 locations
- Trial sites expanded: 1 → 4 locations
- Start date changed from estimate of Jun 1, 2027 to Sep 24, 2026
- Minor Study sites: 1 to 4
Notable Recruitment opened Show 6 more changesShow less
- Start date: Sep 10, 2026 to Jun 1, 2027
- Eligibility criteria expanded, about 11 words
- Interventions modified
- Study sites: 0 to 1
- Secondary endpoints: 3 to 4
- Study description expanded, about 30 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Patients receive carboplatin IV on day 1, PLD IV on day 1 (or gemcitabine IV on days 1 and 8), and bevacizumab (or anti-VEGF antibody biosimilar) IV on days 1 and 15 of each cycle. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. After 6-10 cycles, patients proceed to maintenance therapy. MAINTENANCE: Patients receive bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA at screening and undergo CT and/or MRI and collection of blood samples throughout the trial.
Patients receive SG IV over 1-3 hours on days 1 and 8 and bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. After 6-10 cycles, patients proceed to maintenance therapy. MAINTENANCE: Patients receive bevacizumab (or anti-VEGF antibody biosimilar) IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI and collection of blood samples throughout the trial.
Biologicals: Anti-VEGF Monoclonal Antibody, Bevacizumab, Sacituzumab Govitecan
Procedures: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan
Drugs: Carboplatin, Gemcitabine, Pegylated Liposomal Doxorubicin Hydrochloride
Sites
29 sites in 1 country